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Abstract
Objective: The aim of the study was to provide national estimates of Pap test receipt, by 
birthplace, and percent of lifetime in the United States (US).
Materials and Methods: Pooled nationally representative data (2005, 2008, 2013, 2015) from 
the National Health Interview Survey were used to examine differences in Pap test receipt among 
adult US women by birthplace and percent of lifetime in the US. Descriptive estimates were age-
adjusted. Regression models were adjusted for selected sociodemographic and healthcare access 
and utilization factors and presented as predicted margins.
Results: Foreign-born women 18 years and older were more than twice as likely to have never 
received a Pap test compared with US-born women(18.6% vs 6.8%). Regression models showed 
that foreign-born women from Mexico (9.8%), South America (12.6%), Caribbean (14.6%), 
Southeast Asia (13.7%), Central Asia (20.4%), South Asia (22.9%), Middle East (25.0%), Africa 
(27.8%), Europe (16.4%), and Former Soviet Union (28.2%) were more likely to be unscreened 
compared with US-born women (7.6%). Foreign-born women who spent less than 25% of their 
life in the US had higher prevalence of never having a Pap test (20%) compared with foreign-born 
who spent more than 25% of their life in the US (12.7%).
Conclusions: Using national survey, we found that where a woman is born and the percent of 
her lifetime spent residing in the US do impact whether she gets screened at least once in her 
lifetime.
Impact: These findings may inform cervical cancer screening efforts targeting foreign-born 
women.
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Globally, cervical cancer is the fourth most common cancer in women and the seventh most 
common among all cancers overall, with an estimated 528,000 new cases in 2012.1 The Pap 
smear (Pap test) is a screening method used to detect potentially precancerous and cancerous 
processes in the cervix (opening of the uterus or womb). Since the introduction and 
widespread use of the Pap test in the 1950s, cervical cancer incidence and mortality rates in 
the United States (US) have decreased by more than 70%.2 Still, 11% of US women aged 21 
to 65 years have never been screened for cervical cancer.3 From 1995 to 2000, more than 
half of all new cervical cancer cases occurred among women who were rarely or never 
screened.4 Cervical cancer incidence rates are higher among foreign-born women living in 
the US compared with US-born women,5 yet foreign-born women are less likely to receive 
cervical cancer screening compared with US-born women.6 This disparity is partially 
attributed to birthplace, race, and social disparities.6–8
Thirteen percent of the US population is foreign-born, and this proportion is expected to 
grow to 20% in the next 40 years.9,10 With high cervical cancer incidence rates among this 
subgroup, and foreign-born females constituting 51% of the foreign-born population,9 it is 
important to understand the cervical cancer screening disparities these women face. This 
article uses periodic cancer supplements for recent years from the National Health Interview 
Survey (NHIS) to gain a better understanding of the use of Pap tests for cervical cancer 
screening in the US. We examine lifetime receipt of a Pap test for all women 18 years and 
older and adherence to US Preventive Services Task Force (USPSTF) recommendations for 
cervical cancer screening for women aged 21 to 65 years11 by birthplace and percent of 
lifetime spent in the US.
MATERIALS AND METHODS
Data Source
The NHIS is a multipurpose, cross-sectional health survey of the US civilian 
noninstitutionalized population based on a stratified multistage sampling design of 
households and group quarters (e.g., college dormitories).12 The NHIS data are publicly 
available with some exceptions; some demographic characteristics and geographic variables 
such as country of birth must be accessed through the National Center for Health Statistics 
(NCHS) Research Data Centers. The NHIS does not collect data on immigration status.
Combined 2005, 2008, 2010, 2013, and 2015 NHIS data were used for this report. We 
examined lifetime receipt of a Pap test among women aged 18 years and older without a 
history of hysterectomy (n = 62,333). Worldwide differences in recommended age of first 
Pap test precluded use of other age ranges. We further examined adherence to the USPSTF 
recommendations for cervical cancer screening in women aged 21 to 65 years without a 
history of hysterectomy (n = 49,233). The USPSTF recommends screening for cervical 
cancer every 3 years with cervical cytology (Pap test) alone in women ages 21 to 29 years 
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and either screening every 3 years with Pap test alone or every 5 years with high-risk human 
papillomavirus (HPV) testing alone in women ages 30 to 65 years.11 The use of high-risk 
HPV was not included in analyses because HPV screening data were not available on the 
NHIS for all years used for this analysis.
Study Variables
Women born in the US, a US territory or born abroad to a US citizen, were categorized as 
US-born, and all others were considered foreign-born. Among foreign-born women, 
birthplace was categorized using a modification of NHIS’ geographic region variable. 
Mexico, Central America, and the Caribbean were separated because of the larger number of 
immigrants relative to those from the other regions (South America, Southeast Asia, Central 
Asia, South Asia [Indian Subcontinent], Middle East [Western Asia], Africa, The Former 
Soviet Union [FSU], and Europe [excludes FSU]) included in the study. Because of small 
sample sizes and representation in the overall study population (<1% of study population), 
we assigned foreign-born women from all other regions/countries not listed, to the 
“Elsewhere” category. However, the diverse sociodemographic, economic, and varied 
geographies preclude this category from comparison as a uniformed statistical unit for the 
purposes of this report.
Percent of lifetime living in the US is commonly used as a proxy measure for acculturation. 
Similar to Tsui et al.,6 we calculated percent of lifetime in the US by dividing the number of 
years living in the US by age at interview and then dichotomized into less than 25% and 
25% or more. Lifetime Pap test receipt was determined by a “yes/no” response to the 
question “Have you ever had a Pap smear or Pap test?” Women who responded “no” were 
categorized as never screened. Those who responded “yes” were asked “When did you have 
your most recent Pap test?” Age at interview and response to time of most recent Pap test 
were used to calculate the percentage of women who did not meet the USPSTF 
recommendations for cervical cancer screening with Pap test alone.
Demographic characteristics presented in this report include age, ethnicity, race, highest 
level of education, poverty status, birthplace, and percent of lifetime in the US. Selected 
health, healthcare access, and utilization variables include health status, health insurance 
coverage at the time of interview, usual place of medical care, and number of doctors’ visits 
in the past 12 months. Using the imputed income files, poverty status was calculated from 
poverty thresholds predefined by the US Census Bureau using a specific ratio of income as a 
percentage of the poverty threshold. Health insurance was categorized into 3 mutually 
exclusive categories; persons with more than 1 type of health insurance were assigned to 
their primary insurance category in the following hierarchy: private then public. Uninsured 
included persons who had no coverage as well as those who had only Indian Health Service 
coverage or had only a private plan that paid for 1 type of service such as accidents or dental 
care.
Statistical Analyses
Estimates were calculated using the sample adult sampling weights (adjusted for the number 
of survey years combined in the analysis) and are representative of the civilian, 
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noninstitutionalized population of US women 18 years and older and 21 to 65 years. Unless 
otherwise indicated, estimates were age-adjusted using the 2000 projected US population.13 
Detailed population tables are available from the US Census Bureau. Respondents with 
missing information on healthcare utilization, Pap test receipt (5.6%), birthplace (0.1%), and 
other sociodemographic factors were excluded from the relevant analysis. Point estimates 
and estimates of their variances were calculated using SAS-callable SUDAAN Version 
11.0.0 (RTI International, 2013, Durham, NC), a software package that accounts for the 
complex sample design of NHIS. Estimates were compared using two-sided t tests at the 
0.05 level and assuming independence.
Prevalence estimates for Pap test receipt by birthplace were adjusted for selected 
socioeconomic and health care access and utilization factors, and these were presented as 
predicted margins from logistic regression models. The predictive margin for a given group 
is the average predicted value for a population. Comparisons of Pap test receipt by birthplace 
and percent of lifetime in the US were made as though women in those population 
subgroups had the same sociodemographic characteristics, health status, and selected 
indicators of health care access and utilization. Thus, resulting estimates reflect differences 
by birthplace and length of lifetime in the US only. Statistical comparisons of the differences 
between estimated differences of lifetime Pap test receipt and receipt in the past 3 years 
between selected subpopulations compared with US-born women were also made. Age-
adjusted estimates in associated tables may differ from other age-adjusted estimates based 
on the same data presented elsewhere if different age groups were used in the adjustment 
procedure.
RESULTS
Sociodemographic Characteristics
Foreign-born women represented 16.7% of the study population (see Table 1). Women born 
in Mexico (28.7%), Central and South American countries and the Caribbean (23.4%), and 
Asian countries (27.9%) accounted for most foreign-born women. Nearly half of the 
foreign-born participants identified as Hispanic, whereas 3 quarters of the US-born women 
identified as non-Hispanic white. A larger percentage of foreign-born women (30.7%) had 
less than high school education compared with US-born women (10.2%). Preliminary 
analyses indicated differences in educational attainment by region of birth among foreign-
born women (data not shown). Compared with their US-born counterparts, foreign-born 
women were more likely to not have health insurance (27.4% vs 11.7%), a usual place of 
care (19.9% vs 11.2%), and reported no visits to a healthcare provider within the past 12 
months (21.7% vs 12.0%). Most foreign-born women (72.9%) had spent 25% or more of 
their life in the US.
Pap Test Screening
Estimates Adjusted for Age Only.—Foreign-born women were more than twice as 
likely to have never received a Pap test (18.6% vs 6.8%) as US-born women (see Table 2). 
Among foreign-born women, those who spent less than 25% of their life in the US were 
more likely to be unscreened compared with those who spent 25% or more of their life in the 
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US (25.3% vs 16.3%). For each sociodemographic characteristic examined, foreign-born 
women were more likely to have never received a Pap test compared with US-born women. 
Differences in Pap test receipt also existed by region of birth and percent of lifetime in the 
US (see Figure 1).
Estimates Adjusted for Sociodemographic Characteristics, Health Status, and 
Health Care Access and Utilization.—The relationship between place of birth and 
never receiving a Pap test is attenuated but remains significant for most regions when 
adjusting for selected sociodemographic and healthcare access and utilization characteristics 
(see Figure 1, Table 3). Among women aged 18 years and older, foreign-born women who 
had spent less than 25% of their lifetime in the US were more than twice as likely be 
unscreened (20.0%) compared with US-born women (7.6%) (see Table 3). Foreign-born 
women who had spent 25% or more of their lifetime in the US (12.7%) were also more 
likely to be unscreened compared with US-born women. Women from Mexico (9.8%), 
South America (12.6%), the Caribbean (14.6%), and Southeast Asia (13.1%) were more 
likely to never have a Pap test compared with US-born women. Women born in Europe 
(16.4%) and Central Asia (20.4%) were more than twice as likely as their US-born peers to 
never have a Pap test, whereas those born in FSU (28.2%), Africa (27.8%), Middle East 
(25.0%), and South Asia (22.9%) were more than 3 times as likely to be unscreened. There 
was no significant difference in never having a Pap test between women born in Central 
America (8.9%) and US-born women. Note that preliminary analysis (not shown) showed no 
interaction between survey year and foreign-born status for lifetime Pap receipt (p = .23) or 
recommended screening (p = .38).
Even after adjusting for sociodemographic and health care access and utilization 
characteristics, among women aged 21 and 65 years; foreign-born women who spent less 
than 25% of their lifetime in the US and those who spent 25% or more of their lifetime in 
the US were more likely to not have a Pap test in the past 3 years (26.2% and 21.2%, 
respectively) compared with US-born women (18.9%) (see Table 3). Women from the 
Caribbean (23.3%), Europe (24.9%), FSU (42.8%), Africa (36.8%), Middle East (35.1%), 
Central Asia (28.7%), and South Asia (33.5%) were more likely to not have a Pap test in the 
past 3 years compared US-born women. Conversely, women from Mexico (15.8%) and 
Central America (15.5%) were less likely to not have a Pap test in the past 3 years compared 
with US-born women. There was no significant difference between US-born women and 
foreign-born women from South America (18.8%) and South East Asia (19.3%) in meeting 
recommended USPSTF cervical cancer screening guidelines.
DISCUSSION
Health disparities between foreign- and US-born persons are often attributed to 
socioeconomic differences and dissimilarities in healthcare access and utilization.5,7 In this 
study, even after controlling for those factors, foreign-born women from most regions 
examined were more likely to have never received a Pap test compared with US-born 
women. With regard to meeting the USPSTF cervical cancer screening recommendation, 
foreign-born women from most regions, with the exception of Mexico, Central and South 
America, and Southeast Asia, were more likely to not have had a Pap test in the past 3 years 
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compared with US-born women. The proportion of women who had never received a Pap 
test as well as those who had not been screened in the past 3 years was greater for foreign-
born women who spent less than 25% than those who spent more than 25% of their lifetime 
in US and was also greater for women who spent more than 25% of their lifetime in 
comparison with US-born women.
Tsui et al.6 published a study in 2007 using NHIS data from 2003 and earlier and conducted 
analyses that closely paralleled the current study, where they divided foreign-born women 
based on birthplace as well as percent of time in the US and adjusted for sociodemographic 
and health care utilization factors. Tsui et al.6 reported that foreign-born women were more 
likely to never have a Pap test compared with US-born women, regardless of birthplace and 
percent of time in the US. They also found that differences in Pap test screening rates in the 
past 3 years, between foreign-born and US-born women, were similar to those seen for 
women who never received a Pap test.
Contrary to Tsui et al.,6 we found no significant difference between US-born women and 
foreign-born women from Central America with regard to lifetime Pap test receipt. Contrary 
to Tsui et al.,6 when examining the percentage of women who did not meet USPSTF 
recommendations for cervical cancer screening, we found that women from Mexico, Central 
and South America, and Southeast Asia were more likely or as likely as US-born women to 
have received a Pap test in the past 3 years. This could suggest that in more recent years, the 
likelihood of getting a Pap test in the past 3 years among foreign-born women from these 
countries has increased.
Some of our findings are also consistent with studies conducted outside of the US. 
Researchers in Canada and Norway have shown that foreign-born women were more likely 
to have never received cervical cancer screening compared with native-born women.14,15 
The likelihood of screening for foreign-born women also varied by percentage of lifetime in 
their host country.14,15 In addition, the Norway study found variations in cervical cancer 
screening coverage based on birthplace for some immigrant groups.15
Researchers have provided some explanations for the cervical cancer screening disparity 
observed in foreign-born women. Documented barriers to screening among foreign-born 
women include language, lack of knowledge about preventive care and safety net programs, 
misconceptions about screening and the cause of cervical cancer, fear, embarrassment, 
previous negative experiences, lack of time, and financial concerns related to missing work.
16–20
 Some barriers such as language, lack of knowledge of cervical cancer prevention and 
cause, as well as characteristics tied to culture may be more pronounced in women who have 
spent a smaller percentage of their lifetime in the host country.21 The use and incorporation 
of the Pap test into population-based cervical cancer screening programs have not been fully 
realized in many parts of the world.22 Improvement in or stagnation in availability of 
national cervical cancer prevention and control programs using the Pap test or other 
screening modalities in country of origin may influence observed differences based on 
birthplace.23,24
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In the US, Hispanics account for the largest group of immigrants. Therefore, verbal and 
written translation for health-related materials are more common for the Spanish language.25 
Consequently, Hispanic women have access to more targeted health services and cervical 
cancer screening programs with culturally appropriate bilingual information.26 This may 
further explain differences in Pap test receipt among foreign-born women from Mexico, 
South America, and Central America compared with foreign-born women from non-Spanish 
speaking countries.
Systematic reviews have found that culturally appropriate, targeted interventions are 
effective at increasing cancer screening rates.27,28 Common elements among these 
interventions include using language-based disease specific materials, involving patient 
navigators, providing cultural awareness training for health care providers, and removing 
barriers to screening. Research is underway for novel ideals such as providing self-sampling 
test kits to make screening convenient for people, including foreign-born persons.29 Further 
research could examine barriers to interventions to increase cervical cancer screening among 
the foreign-born population.
The NHIS is a cross-sectional survey where current and historical information are collected 
at 1 point in time. Data are based on self-report, which may be limited by respondents’ 
willingness to provide information, inaccuracy in recall, inflating self-assessment, question 
comprehension, and cultural differences.30 To increase the precision of estimates of Pap test 
receipt at detailed levels, we combined data from 5 periodic cancer supplements spanning 11 
years. Although there are significant reductions in sampling errors by combining data across 
years, there are also limitations associated with this estimation procedure in that it only 
provides an average across the years and does not represent a particular point in time. 
However, preliminary analyses using Joinpoint (National Cancer Institute, 2017, Bethesda, 
MD) software showed that there was no significant trend in ever having a Pap test across the 
survey years within the study. A major strength of these analyses is that the data are from a 
nationally representative sample of US women, thus allowing for population estimates. The 
large sample size allows for estimation of receipt of a Pap test by several population 
subgroups and other self-reported health characteristics collected in NHIS.
CONCLUSIONS
Where a woman is born and the percent of her lifetime residing in the US may play a role in 
whether she receives a Pap test at least once in her lifetime and if she is likely to be screened 
regularly. Foreign-born women have a higher incidence of cervical cancer5 yet are less likely 
to receive a Pap test compared with US-born women. These findings may inform cervical 
cancer screening efforts targeting foreign-born women.
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FIGURE 1. 
Age-adjusted estimates of never having a Pap test by birthplace and percent of lifetime in the 
United States, women 18 years or older: National Health Interview Survey 2005, 2008, 
2010, 2013, and 2015. Note: The denominator used for analysis is US women 18 years or 
older, who never had a hysterectomy. Percents shown are age adjusted using the projected 
2000 US population as the standard population and using the following age groups: 18–20, 
21–29, 30–39, 40–49, 50–59, 60–64, and ≥65 years. Percents were weighted using the 
sample adult weight adjusted for 5 years of data. Birthplace is mutually exclusive. 
aSignificantly different from US-born (p < .05). bSignificantly different from ≥25% of 
lifetime in the United States (p < .05).
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